8-K 1 form_8-k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8‑K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): August 23, 2019
 
IRADIMED CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
 
001-36534
73-1408526
  
 
(Commission File Number)
(IRS Employer Identification No.)
  
       
       
 
1025 Willa Springs Dr., Winter Springs, FL
(Address of Principal Executive Offices)
32708
(Zip Code)
  


(407) 677-8022
(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⌧
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class:
  
Trading Symbol
  
Name of each exchange on which registered:
Common stock, par value $0.0001
  
IRMD
  
NASDAQ Capital Market

 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 23, 2019, Iradimed Corporation (the “Company”) entered into the First Amended and Restated Separation Agreement (the “Agreement”) with John McCreery resulting from Mr. McCreery’s retirement.

Pursuant to his Agreement, Mr. McCreery will continue to serve as the Company’s Chief Operating Officer through the period ending Monday, January 6, 2020 (the “Retirement Date”), will remain eligible to receive the 2019 annual bonus, and will receive a one-time addition of 40 hours to his total paid time-off balance. Additionally, the Company has agreed to accelerate the vesting of the third tranche of Mr. McCreery’s initial restricted stock unit award to his Retirement Date, amounting to 15,625 shares of the Company’s common stock.

This summary description is qualified in its entirety by reference to the First Amended and Restated Separation Agreement between the Company and Mr. McCreery, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits

10.1
First Amended and Restated Separation Agreement, dated as of August 23, 2019 by and between Iradimed Corporation and John McCreery
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  IRADIMED CORPORATION  
       
       
       
Date: August 26, 2019      
 
By:
  
/s/   Chris Scott
  
 
Name:
Chris Scott
  
 
Title:
Chief Financial Officer
  







EXHIBIT INDEX

Exhibit No.
Document